Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) reported EBITDA Margin of 1021.71% for Q1 2025, up 136402.0% year-over-year from N/an in Q1 2024, and up 504.25% on a QoQ basis from 252.74% in Q4 2024.
Whitehawk Therapeutics (WHWK) has 7 years of EBITDA Margin data on file, last reported at 1021.71% in Q1 2025.
- Quarterly EBITDA Margin rose 136402.0% year-over-year to 1021.71% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 286.8% (down 4163.0% YoY) and the FY2025 annual result came in at 286.8%, down 4163.0% from the prior year.
- EBITDA Margin advanced to 1021.71% in Q1 2025 per WHWK's latest filing, from 252.74% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1021.71% in Q1 2025 and bottomed at 3405.83% in Q1 2021.
- The 5-year median for EBITDA Margin is 266.48% (2022), against an average of 421.8%.
- The widest annual swing landed in 2021, when EBITDA Margin slumped 17436 bps; it then surged 280518 bps in 2022.
- Tracing WHWK's EBITDA Margin over 5 years: stood at 118.84% in 2021, then slumped by 124 bps to 266.48% in 2022, then climbed by 4 bps to 256.5% in 2023, then grew by 1 bps to 252.74% in 2024, then jumped by 504 bps to 1021.71% in 2025.
- Per Business Quant, the three latest WHWK EBITDA Margin figures stand at 1021.71% (Q1 2025), 252.74% (Q4 2024), and 173.04% (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1,021.71% |
| Dec 31, 2024 | -252.74% |
| Sep 30, 2024 | -173.04% |
| Jun 30, 2024 | -236.32% |
| Mar 31, 2024 | -342.31% |
| Dec 31, 2023 | -256.50% |
| Sep 30, 2023 | -273.10% |
| Jun 30, 2023 | -289.95% |
| Mar 31, 2023 | -258.05% |
| Dec 31, 2022 | -266.48% |
| Sep 30, 2022 | -343.30% |
| Jun 30, 2022 | -531.54% |
| Mar 31, 2022 | -600.65% |
| Dec 31, 2021 | -118.84% |
| Mar 31, 2021 | -3,405.83% |
| Dec 31, 2020 | 55.52% |
| Sep 30, 2020 | -1,358.87% |
| Jun 30, 2020 | 61.71% |
| Dec 31, 2018 | -413,534.42% |
| Sep 30, 2018 | 59.49% |
| Jun 30, 2018 | -452.73% |